{
    "hands_on_practices": [
        {
            "introduction": "The cornerstone of any brachytherapy plan is determining the necessary source strength to achieve the desired therapeutic dose rate. This exercise introduces the fundamental principle of superposition, where the total dose rate at the tumor apex is calculated by summing the contributions from each radioactive seed in the plaque . By working through this problem, you will practice a core skill in treatment planning: calculating the required total air-kerma strength for a plaque to meet a specific dosimetric prescription at the tumor's apex.",
            "id": "4713145",
            "problem": "A clinical ocular plaque brachytherapy plan aims to deliver a uniform dose rate at the tumor apex using multiple seeds affixed to a concave plaque. The tumor apex is defined as the point along the central axis of the plaque at a prescribed height above the sclera. Assume that superposition of individual seed contributions to the apex dose rate is valid, and that a single aggregate per-seed dosimetric contribution factor (i.e., the product of seed dose rate constant, geometry, anisotropy, and radial dose functions evaluated at the apex) has been characterized for this plaque configuration. Specifically, the average per-seed aggregate factor equals $0.04\\,\\text{cGy}\\,\\text{h}^{-1}\\,\\text{U}^{-1}$, meaning that each seed with air-kerma strength contributes $0.04\\,\\text{cGy}\\,\\text{h}^{-1}$ per unit air-kerma strength $U$ at the apex.\n\nThe plan’s target apex dose rate is $0.8\\,\\text{Gy}\\,\\text{h}^{-1}$. Compute the required sum of seed air-kerma strengths $\\sum S_{k}$ that must be loaded into the plaque to meet the target apex dose rate, assuming the aggregate factor applies uniformly to all seeds. Express your final answer in $U$ and round to three significant figures. State any unit conversions you use.",
            "solution": "The problem statement is critically evaluated for validity prior to any attempt at a solution.\n\n### Step 1: Extract Givens\nThe following data and conditions are explicitly provided in the problem statement:\n- **Principle of Superposition**: The total dose rate at the tumor apex is the sum of contributions from individual seeds.\n- **Aggregate Dosimetric Factor ($F$)**: The average per-seed aggregate factor is $F = 0.04\\,\\text{cGy}\\,\\text{h}^{-1}\\,\\text{U}^{-1}$. This factor represents the dose rate contribution at the apex per unit air-kerma strength ($U$) from a single seed.\n- **Uniformity Assumption**: The aggregate factor $F$ applies uniformly to all seeds in the plaque.\n- **Target Apex Dose Rate ($\\dot{D}_{\\text{target}}$)**: The desired dose rate at the tumor apex is $\\dot{D}_{\\text{target}} = 0.8\\,\\text{Gy}\\,\\text{h}^{-1}$.\n- **Objective**: Compute the required sum of seed air-kerma strengths, denoted as $\\sum S_{k}$, needed to achieve the target dose rate.\n- **Output Requirements**: The final answer must be in units of $U$ and rounded to three significant figures. Any unit conversions must be stated.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the required criteria:\n- **Scientifically Grounded**: The problem is based on the fundamental principles of brachytherapy dosimetry, specifically the concepts of air-kerma strength ($S_k$), dose rate ($\\dot{D}$), and the principle of superposition for dose calculation. These concepts are central to the AAPM TG-43 formalism used in clinical medical physics. The given numerical values are physically plausible for ocular brachytherapy.\n- **Well-Posed**: The problem provides all necessary information to determine a unique solution. It defines the relationship between seed strength and dose rate contribution, specifies the target dose rate, and asks for a single, well-defined quantity ($\\sum S_{k}$).\n- **Objective**: The problem is stated using precise, quantitative language, free of ambiguity or subjective claims.\n\nThe problem does not exhibit any of the enumerated flaws. It is not scientifically unsound, non-formalizable, incomplete, contradictory, unrealistic, or ill-posed. The use of an average aggregate factor is a valid simplification for constructing a solvable problem rooted in a real-world application. Therefore, the problem is deemed **valid**.\n\n### Solution\nThe total dose rate at the tumor apex, $\\dot{D}_{\\text{apex}}$, is the sum of the dose rate contributions from each individual seed loaded into the plaque. Let $N$ be the total number of seeds, and let $S_k$ be the air-kerma strength of the $k$-th seed in units of $U$.\n\nThe dose rate contribution from the $k$-th seed, $\\dot{D}_k$, is the product of its air-kerma strength $S_k$ and the aggregate dosimetric factor $F$.\n$$\n\\dot{D}_k = F \\cdot S_k\n$$\nAccording to the principle of superposition, the total dose rate at the apex is the sum of the individual contributions:\n$$\n\\dot{D}_{\\text{apex}} = \\sum_{k=1}^{N} \\dot{D}_k = \\sum_{k=1}^{N} (F \\cdot S_k)\n$$\nThe problem states that the aggregate factor $F$ is uniform for all seeds. Therefore, it can be factored out of the summation:\n$$\n\\dot{D}_{\\text{apex}} = F \\cdot \\sum_{k=1}^{N} S_k\n$$\nThe objective is to find the total air-kerma strength, $\\sum S_k$, required to achieve the target apex dose rate, $\\dot{D}_{\\text{target}}$. We set $\\dot{D}_{\\text{apex}} = \\dot{D}_{\\text{target}}$:\n$$\n\\dot{D}_{\\text{target}} = F \\cdot \\sum_{k=1}^{N} S_k\n$$\nSolving for the sum of the air-kerma strengths yields:\n$$\n\\sum_{k=1}^{N} S_k = \\frac{\\dot{D}_{\\text{target}}}{F}\n$$\nThe given values are $\\dot{D}_{\\text{target}} = 0.8\\,\\text{Gy}\\,\\text{h}^{-1}$ and $F = 0.04\\,\\text{cGy}\\,\\text{h}^{-1}\\,\\text{U}^{-1}$. The units of dose rate are Gray per hour ($\\text{Gy}\\,\\text{h}^{-1}$) and centiGray per hour ($\\text{cGy}\\,\\text{h}^{-1}$). A unit conversion is necessary to ensure dimensional consistency. We will convert $\\dot{D}_{\\text{target}}$ from $\\text{Gy}\\,\\text{h}^{-1}$ to $\\text{cGy}\\,\\text{h}^{-1}$.\n\nThe conversion factor is $1\\,\\text{Gy} = 100\\,\\text{cGy}$.\n$$\n\\dot{D}_{\\text{target}} = 0.8\\,\\text{Gy}\\,\\text{h}^{-1} \\times \\left(\\frac{100\\,\\text{cGy}}{1\\,\\text{Gy}}\\right) = 80\\,\\text{cGy}\\,\\text{h}^{-1}\n$$\nNow, substitute the numerical values into the equation for the total air-kerma strength:\n$$\n\\sum_{k=1}^{N} S_k = \\frac{80\\,\\text{cGy}\\,\\text{h}^{-1}}{0.04\\,\\text{cGy}\\,\\text{h}^{-1}\\,\\text{U}^{-1}}\n$$\nThe units of $\\text{cGy}\\,\\text{h}^{-1}$ cancel, leaving the result in units of $U$.\n$$\n\\sum_{k=1}^{N} S_k = \\frac{80}{0.04}\\ U = \\frac{80}{4 \\times 10^{-2}}\\ U = 20 \\times 10^2\\ U = 2000\\ U\n$$\nThe problem requires the answer to be rounded to three significant figures. To express $2000$ with three significant figures, we write it in scientific notation.\n$$\n\\sum_{k=1}^{N} S_k = 2.00 \\times 10^3\\ U\n$$\nThis is the total air-kerma strength that must be loaded into the plaque to deliver the target dose rate at the tumor apex.",
            "answer": "$$\\boxed{2.00 \\times 10^{3}}$$"
        },
        {
            "introduction": "Effective treatment planning involves a critical balance between eradicating the tumor and preserving the function of nearby healthy tissues, a paramount concern in ophthalmology. This hands-on problem challenges you to think like a clinical physicist, devising a strategy to spare the dose-sensitive fovea while treating a nearby choroidal melanoma . You will evaluate how adjusting plaque position, modifying individual seed strengths, and exploiting the anisotropic nature of the radiation source can be combined to achieve a superior therapeutic ratio.",
            "id": "4713107",
            "problem": "A choroidal melanoma is located approximately $2$ $\\mathrm{mm}$ temporal to the macula (the macular center at the fovea), with an apex height of $3$ $\\mathrm{mm}$ above the inner scleral surface. A gold-backed iodine-$125$ plaque is to be used for brachytherapy. For planning, adopt the following simplified but clinically plausible geometric model to reason from first principles:\n\n- Place the fovea at in-plane coordinate $x=0$ and the inner scleral surface at depth $z=0$. The tumor apex is at $(x,z) = ( +2\\,\\text{mm}, +3\\,\\text{mm} )$. The plaque with its seed array is mounted on the outer scleral surface, modeled at $z=-1\\,\\text{mm}$.\n- In the baseline centered configuration, the plaque’s central seed (dominant contributor to apex dose) lies at $x=+2\\,\\text{mm}$, directly external to the apex. The nearest seed to the fovea (dominant contributor to macular dose) lies at $x=+1\\,\\text{mm}$.\n- Assume iodine-$125$ seed emission anisotropy can be exploited by orienting seed end-caps such that the direction toward the fovea has an anisotropy factor $F_{\\text{fovea}} = 0.8$, whereas the direction toward the tumor apex can be taken as $F_{\\text{apex}} = 1.0$ for near-transverse geometry. Assume the radial dose function is approximately unity over these small distances.\n- Let each seed’s dosimetric strength be proportional to its activity, denoted by $A$ for the baseline plan. In the baseline centered plan, the central seed has activity $A_c = A$ and the nearest-to-fovea seed has activity $A_n = A$.\n\nUsing the above geometry and physical assumptions, the clinical objective is to construct a planning approach that:\n- Maintains the apex dose rate within $\\pm 5\\%$ of the baseline centered plan’s apex dose rate.\n- Reduces the foveal dose rate by at least $50\\%$ relative to the baseline centered plan’s foveal dose rate.\n\nWhich of the following planning strategies best meets the objective?\n\nA. Keep the plaque centered over the tumor base with uniform seed loading ($A_c = A_n = A$) and no special seed orientation.\n\nB. Shift the plaque $+1$ $\\mathrm{mm}$ further temporal (away from the fovea), increase the central seed activity by $6\\%$ (so $A_c = 1.06\\,A$), halve the activity of the nearest-to-fovea seed ($A_n = 0.5\\,A$), and orient the nearest-to-fovea seed’s end-cap toward the fovea ($F_{\\text{fovea}} = 0.8$), while keeping the apex direction effectively transverse ($F_{\\text{apex}} = 1.0$).\n\nC. Shift the plaque $-1$ $\\mathrm{mm}$ nasally (toward the fovea), increase the central seed activity by $6\\%$ ($A_c = 1.06\\,A$), keep the nearest-to-fovea seed activity unchanged ($A_n = A$), and do not use anisotropic orientation ($F_{\\text{fovea}} = F_{\\text{apex}} = 1.0$).\n\nD. Keep the plaque centered, reduce the nearest-to-fovea seed activity to $25\\%$ ($A_n = 0.25\\,A$), increase the central seed activity by $10\\%$ ($A_c = 1.10\\,A$), and do not use anisotropic orientation ($F_{\\text{fovea}} = F_{\\text{apex}} = 1.0$).\n\nE. Use a larger-diameter plaque centered over the tumor with uniform loading ($A_c = A_n = A$), thereby introducing additional seeds closer to the fovea.\n\nSelect the single best option.",
            "solution": "The problem statement must first be validated for scientific and logical integrity before a solution is attempted.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n-   **Tumor Geometry:** A choroidal melanoma is located approximately $2\\,\\text{mm}$ temporal to the macula. Its apex height is $3\\,\\text{mm}$ above the inner scleral surface.\n-   **Coordinate System:**\n    -   The fovea is at the in-plane coordinate $x=0$.\n    -   The inner scleral surface is at depth $z=0$.\n    -   The fovea's coordinates are therefore $(x,z) = (0, 0)$.\n    -   The tumor apex is at $(x,z) = ( +2\\,\\text{mm}, +3\\,\\text{mm} )$.\n    -   The plaque is mounted on the outer scleral surface, modeled at $z=-1\\,\\text{mm}$.\n-   **Baseline Centered Configuration:**\n    -   The plaque's central seed is at $x=+2\\,\\text{mm}$, so its coordinate is $S_c=(+2\\,\\text{mm}, -1\\,\\text{mm})$.\n    -   The nearest seed to the fovea is at $x=+1\\,\\text{mm}$, so its coordinate is $S_n=(+1\\,\\text{mm}, -1\\,\\text{mm})$.\n-   **Dosimetric Assumptions:**\n    -   The problem states to reason from simplified first principles, where the dose contribution to the apex is dominated by the central seed, and the dose contribution to the fovea is dominated by the nearest-to-fovea seed.\n    -   Anisotropy factor for the direction toward the fovea (if oriented): $F_{\\text{fovea}} = 0.8$.\n    -   Anisotropy factor for the direction toward the apex: $F_{\\text{apex}} = 1.0$.\n    -   The radial dose function is approximately unity.\n    -   Seed dosimetric strength is proportional to its activity, $A$.\n-   **Baseline Plan Activities:**\n    -   Central seed activity: $A_c = A$.\n    -   Nearest-to-fovea seed activity: $A_n = A$.\n-   **Clinical Objectives:**\n    1.  Maintain the apex dose rate within $\\pm 5\\%$ of the baseline centered plan's apex dose rate.\n    2.  Reduce the foveal dose rate by at least $50\\%$ relative to the baseline centered plan's foveal dose rate.\n\n**Step 2: Validate Using Extracted Givens**\n\n-   **Scientific Groundedness:** The problem uses a simplified model based on the American Association of Physicists in Medicine (AAPM) Task Group No. 43 (TG-43) brachytherapy formalism. The dose rate $\\dot{D}$ from a source is proportional to its activity, an inverse square law in distance ($1/r^2$), an anisotropy function $F$, and a radial dose function $g(r)$. The problem's simplifications ($g(r) \\approx 1$ and considering only dominant seed contributions) are explicitly stated and create a solvable, physically-based scenario. The use of iodine-$125$ plaques for choroidal melanoma and the geometric parameters are clinically realistic. The problem is scientifically sound.\n-   **Well-Posedness:** The problem is well-posed. It provides all necessary data and a clear set of criteria to evaluate the proposed strategies. A unique best option can be determined through calculation.\n-   **Objectivity:** The problem is stated in precise, objective language. There are no subjective or opinion-based elements.\n-   **Completeness and Consistency:** The setup is self-contained and free of contradictions. The coordinate system and simplified physics are clearly defined.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. A rigorous solution can be derived.\n\n### Derivation and Solution\n\nThe problem specifies a simplified dosimetric model. Based on the TG-43 formalism and the given assumptions, the dose rate $\\dot{D}$ at a point from a single seed is proportional to the seed's activity $A$ and its anisotropy factor $F$ for that direction, and inversely proportional to the square of the distance $r$ from the seed to the point. The radial dose function $g(r)$ is taken as unity. We can express this as:\n$$ \\dot{D} = k \\frac{A \\cdot F}{r^2} $$\nwhere $k$ is a constant of proportionality that will cancel out in all relative comparisons.\n\n**1. Baseline Plan Analysis**\n\nFirst, we calculate the dose rates for the baseline configuration. The problem uses simplified coordinates without units, so we follow this convention for calculation.\n-   **Points of Interest:** Apex $P_{\\text{apex}} = (2, 3)$ and Fovea $P_{\\text{fovea}} = (0, 0)$.\n-   **Baseline Seed Locations:** Central seed $S_c = (2, -1)$ and nearest-to-fovea seed $S_n = (1, -1)$.\n-   **Baseline Activities:** $A_c = A$, $A_n = A$.\n-   **Baseline Anisotropy:** No special orientation is specified for the baseline plan, so we assume isotropic emission, i.e., $F=1.0$ for all directions.\n\n-   **Distance from central seed to apex:**\n    $r_{c \\to \\text{apex}} = \\sqrt{(2-2)^2 + (3-(-1))^2} = \\sqrt{0^2 + 4^2} = 4\\,\\text{mm}$.\n-   **Distance from nearest seed to fovea:**\n    $r_{n \\to \\text{fovea}} = \\sqrt{(1-0)^2 + (-1-0)^2} = \\sqrt{1^2 + (-1)^2} = \\sqrt{2}\\,\\text{mm}$.\n\n-   **Baseline Apex Dose Rate ($\\dot{D}_{\\text{apex, base}}$):** Dominated by the central seed.\n    $$ \\dot{D}_{\\text{apex, base}} = k \\frac{A_c \\cdot F_{\\text{apex}}}{r_{c \\to \\text{apex}}^2} = k \\frac{A \\cdot 1.0}{4^2} = \\frac{k A}{16} $$\n-   **Baseline Foveal Dose Rate ($\\dot{D}_{\\text{fovea, base}}$):** Dominated by the nearest-to-fovea seed.\n    $$ \\dot{D}_{\\text{fovea, base}} = k \\frac{A_n \\cdot F_{\\text{fovea}}}{r_{n \\to \\text{fovea}}^2} = k \\frac{A \\cdot 1.0}{(\\sqrt{2})^2} = \\frac{k A}{2} $$\n\n**2. Clinical Objectives (Quantitative)**\n\n1.  Apex Dose Rate Ratio: $0.95 \\le \\frac{\\dot{D}_{\\text{apex, new}}}{\\dot{D}_{\\text{apex, base}}} \\le 1.05$.\n2.  Foveal Dose Rate Ratio: $\\frac{\\dot{D}_{\\text{fovea, new}}}{\\dot{D}_{\\text{fovea, base}}} \\le 0.50$.\n\n**3. Evaluation of Options**\n\n**A. Keep the plaque centered over the tumor base with uniform seed loading ($A_c = A_n = A$) and no special seed orientation.**\nThis is the baseline plan itself.\n-   Apex dose ratio: $\\frac{\\dot{D}_{\\text{apex, base}}}{\\dot{D}_{\\text{apex, base}}} = 1.0$. This meets objective 1.\n-   Foveal dose ratio: $\\frac{\\dot{D}_{\\text{fovea, base}}}{\\dot{D}_{\\text{fovea, base}}} = 1.0$. This does not meet objective 2, as $1.0 \\not\\le 0.50$.\n**Verdict: Incorrect.**\n\n**B. Shift the plaque $+1\\,\\text{mm}$ further temporal (away from the fovea), increase the central seed activity by $6\\%$ (so $A_c = 1.06\\,A$), halve the activity of the nearest-to-fovea seed ($A_n = 0.5\\,A$), and orient the nearest-to-fovea seed’s end-cap toward the fovea ($F_{\\text{fovea}} = 0.8$), while keeping the apex direction effectively transverse ($F_{\\text{apex}} = 1.0$).**\n-   **New Seed Locations:** Shift is $+1$ in $x$. $S'_c = (2+1, -1) = (3,-1)$. The seed that was at $x=1$ is now at $x=2$; this is the new \"nearest-to-fovea\" seed in the problem's simplified logic, $S'_n = (1+1, -1) = (2,-1)$.\n-   **New Parameters:** $A'_c = 1.06A$, $A'_n = 0.5A$, $F'_{\\text{fovea}} = 0.8$, $F'_{\\text{apex}} = 1.0$.\n-   **New Distances:**\n    $r'_{c \\to \\text{apex}} = \\sqrt{(3-2)^2 + (-1-3)^2} = \\sqrt{1^2 + (-4)^2} = \\sqrt{17}\\,\\text{mm}$.\n    $r'_{n \\to \\text{fovea}} = \\sqrt{(2-0)^2 + (-1-0)^2} = \\sqrt{2^2 + (-1)^2} = \\sqrt{5}\\,\\text{mm}$.\n-   **New Dose Rates:**\n    $\\dot{D}_{\\text{apex, B}} = k \\frac{1.06A \\cdot 1.0}{(\\sqrt{17})^2} = \\frac{1.06 k A}{17}$.\n    $\\dot{D}_{\\text{fovea, B}} = k \\frac{0.5A \\cdot 0.8}{(\\sqrt{5})^2} = \\frac{0.4 k A}{5} = \\frac{k A}{12.5}$.\n-   **Check Objectives:**\n    Apex Ratio: $\\frac{\\dot{D}_{\\text{apex, B}}}{\\dot{D}_{\\text{apex, base}}} = \\frac{1.06 k A / 17}{k A / 16} = \\frac{1.06 \\times 16}{17} = \\frac{16.96}{17} \\approx 0.9976$.\n    Since $0.95 \\le 0.9976 \\le 1.05$, objective 1 is met.\n    Foveal Ratio: $\\frac{\\dot{D}_{\\text{fovea, B}}}{\\dot{D}_{\\text{fovea, base}}} = \\frac{k A / 12.5}{k A / 2} = \\frac{2}{12.5} = \\frac{4}{25} = 0.16$.\n    Since $0.16 \\le 0.50$, objective 2 is met.\n**Verdict: Correct.**\n\n**C. Shift the plaque $-1\\,\\text{mm}$ nasally (toward the fovea), increase the central seed activity by $6\\%$ ($A_c = 1.06\\,A$), keep the nearest-to-fovea seed activity unchanged ($A_n = A$), and do not use anisotropic orientation ($F_{\\text{fovea}} = F_{\\text{apex}} = 1.0$).**\n-   **New Seed Locations:** Shift is $-1$ in $x$. $S'_c = (2-1, -1) = (1,-1)$. The seed that was at $x=1$ is now at $x=0$, $S'_n = (1-1, -1) = (0,-1)$.\n-   **New Parameters:** $A'_c = 1.06A$, $A'_n = A$, $F'=1.0$.\n-   **New Distances:**\n    $r'_{c \\to \\text{apex}} = \\sqrt{(1-2)^2 + (-1-3)^2} = \\sqrt{(-1)^2 + (-4)^2} = \\sqrt{17}\\,\\text{mm}$.\n    $r'_{n \\to \\text{fovea}} = \\sqrt{(0-0)^2 + (-1-0)^2} = \\sqrt{0^2 + (-1)^2} = 1\\,\\text{mm}$.\n-   **New Dose Rates:**\n    $\\dot{D}_{\\text{apex, C}} = k \\frac{1.06A \\cdot 1.0}{(\\sqrt{17})^2} = \\frac{1.06 k A}{17}$.\n    $\\dot{D}_{\\text{fovea, C}} = k \\frac{A \\cdot 1.0}{1^2} = k A$.\n-   **Check Objectives:**\n    Apex Ratio: $\\frac{1.06 k A / 17}{k A / 16} \\approx 0.9976$. Objective 1 is met.\n    Foveal Ratio: $\\frac{k A}{k A / 2} = 2.0$.\n    Since $2.0 \\not\\le 0.50$, objective 2 is not met. Shifting the plaque toward the fovea dramatically increases its dose, which is counterproductive.\n**Verdict: Incorrect.**\n\n**D. Keep the plaque centered, reduce the nearest-to-fovea seed activity to $25\\%$ ($A_n = 0.25\\,A$), increase the central seed activity by $10\\%$ ($A_c = 1.10\\,A$), and do not use anisotropic orientation ($F_{\\text{fovea}} = F_{\\text{apex}} = 1.0$).**\n-   **New Seed Locations:** Same as baseline. $S_c=(2,-1)$, $S_n=(1,-1)$.\n-   **New Parameters:** $A'_c = 1.10A$, $A'_n = 0.25A$, $F'=1.0$.\n-   **New Dose Rates:**\n    $\\dot{D}_{\\text{apex, D}} = k \\frac{1.10A \\cdot 1.0}{4^2} = \\frac{1.10 k A}{16}$.\n    $\\dot{D}_{\\text{fovea, D}} = k \\frac{0.25A \\cdot 1.0}{(\\sqrt{2})^2} = \\frac{0.25 k A}{2}$.\n-   **Check Objectives:**\n    Apex Ratio: $\\frac{1.10 k A / 16}{k A / 16} = 1.10$.\n    Since $1.10 > 1.05$, this violates the $\\pm 5\\%$ constraint of objective 1.\n    Foveal Ratio: $\\frac{0.25 k A / 2}{k A / 2} = 0.25$. This meets objective 2.\n    However, the strategy must meet both objectives.\n**Verdict: Incorrect.**\n\n**E. Use a larger-diameter plaque centered over the tumor with uniform loading ($A_c = A_n = A$), thereby introducing additional seeds closer to the fovea.**\nThis is a qualitative description. A larger plaque, centered at $x=2\\,\\text{mm}$, would have a wider seed distribution. Seeds would be placed at locations with $x1\\,\\text{mm}$. For example, a seed might be placed at $x=0\\,\\text{mm}$, directly external to the fovea. This new seed, being only $1\\,\\text{mm}$ from the fovea (at $z=-1\\,\\text{mm}$ vs. fovea at $z=0$), would deliver a very high dose, thus substantially increasing the total foveal dose. This is the opposite of the desired outcome.\n**Verdict: Incorrect.**\n\nBased on this comprehensive analysis, only option B successfully satisfies both clinical objectives.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "The physical dose in Gray ($Gy$) does not tell the whole story; the biological effect of radiation depends heavily on how that dose is delivered over time. This practice delves into the radiobiological principles of the Linear-Quadratic (LQ) model to translate a continuous low-dose-rate brachytherapy prescription into an Equivalent Dose in $2\\,\\text{Gy}$ fractions (EQD2) . Mastering this calculation allows you to compare the biological impact of a plaque treatment with standard external beam radiotherapy regimens, providing a deeper insight into its therapeutic potential and expected tissue response.",
            "id": "4713101",
            "problem": "A patient with a choroidal melanoma undergoes Ophthalmic Plaque Brachytherapy using a radioactive seed plaque. Assume the plaque delivers a continuous, approximately constant dose rate over the implant duration. The prescription to the tumor apex is a total dose of $85\\,\\text{Gy}$, delivered over $120\\,\\text{h}$. The stated nominal dose rate at the apex is $\\dot{D} = 0.7\\,\\text{Gy}\\,\\text{h}^{-1}$, the tissue linear–quadratic parameter ratio is $\\alpha/\\beta = 3\\,\\text{Gy}$, and the mono-exponential sublethal damage repair rate constant is $\\mu = 0.3\\,\\text{h}^{-1}$.\n\nStarting from the Linear–Quadratic (LQ) model for cell survival with time-dependent dose delivery and mono-exponential repair, and using the Biologically Effective Dose (BED) and the Equivalent Dose in $2\\,\\text{Gy}$ fractions (EQD2) definitions, derive the appropriate expressions needed for continuous low-dose-rate irradiation. State clearly any modeling assumptions you adopt (e.g., constancy of dose rate, repair kinetics, and repopulation). Then compute the EQD2 corresponding to the described plaque treatment.\n\nRound your final numerical answer to three significant figures and express it in Gray ($\\mathrm{Gy}$). Provide only the single numerical value as the final answer.",
            "solution": "The Linear–Quadratic (LQ) model for cell survival under a general time-dependent irradiation expresses the surviving fraction as\n$$\nS = \\exp\\!\\left[-\\left(\\alpha D + \\beta \\int_{0}^{T}\\!\\!\\int_{0}^{T} R(t)\\,R(t')\\,\\exp\\!\\left(-\\mu |t-t'|\\right)\\,\\mathrm{d}t\\,\\mathrm{d}t'\\right)\\right],\n$$\nwhere $D$ is the total physical dose, $T$ is the irradiation duration, $R(t)$ is the dose rate, $\\alpha$ and $\\beta$ are LQ parameters, and $\\mu$ is the mono-exponential repair rate constant for sublethal damage. The Biologically Effective Dose (BED) is defined via $S = \\exp(-\\alpha \\,\\mathrm{BED})$, which yields\n$$\n\\mathrm{BED} = D + \\frac{\\beta}{\\alpha}\\,\\int_{0}^{T}\\!\\!\\int_{0}^{T} R(t)\\,R(t')\\,\\exp\\!\\left(-\\mu |t-t'|\\right)\\,\\mathrm{d}t\\,\\mathrm{d}t'.\n$$\nUsing the ratio $\\alpha/\\beta$, we write $\\beta/\\alpha = 1/(\\alpha/\\beta)$.\n\nFor continuous low-dose-rate irradiation at approximately constant dose rate $R(t) = \\dot{D}$ over $t \\in [0,T]$, we evaluate the double integral:\n$$\nI \\equiv \\int_{0}^{T}\\!\\!\\int_{0}^{T} \\exp\\!\\left(-\\mu |t-t'|\\right)\\,\\mathrm{d}t\\,\\mathrm{d}t' = 2\\int_{0}^{T}\\!\\!\\int_{0}^{t} \\exp\\!\\left[-\\mu (t-t')\\right]\\,\\mathrm{d}t'\\,\\mathrm{d}t.\n$$\nLet $u = t - t'$, so for each fixed $t$ the inner integral becomes\n$$\n\\int_{0}^{t} \\exp(-\\mu u)\\,\\mathrm{d}u = \\frac{1 - \\exp(-\\mu t)}{\\mu}.\n$$\nTherefore,\n$$\nI = 2\\int_{0}^{T} \\frac{1 - \\exp(-\\mu t)}{\\mu}\\,\\mathrm{d}t = \\frac{2}{\\mu}\\left[T - \\frac{1 - \\exp(-\\mu T)}{\\mu}\\right].\n$$\nWith $R(t) = \\dot{D}$, the quadratic dose integral becomes\n$$\n\\int_{0}^{T}\\!\\!\\int_{0}^{T} R(t)\\,R(t')\\,\\exp\\!\\left(-\\mu |t-t'|\\right)\\,\\mathrm{d}t\\,\\mathrm{d}t' = \\dot{D}^{2}\\,I = \\dot{D}^{2}\\,\\frac{2}{\\mu}\\left[T - \\frac{1 - \\exp(-\\mu T)}{\\mu}\\right].\n$$\nIt is conventional to define the Lea–Catcheside protraction factor $G$ for constant rate delivery by\n$$\nG \\equiv \\frac{2}{\\mu T}\\left(1 - \\frac{1 - \\exp(-\\mu T)}{\\mu T}\\right),\n$$\nwhich ensures\n$$\n\\dot{D}^{2}\\,I = D^{2}\\,G, \\quad \\text{with } D = \\dot{D}\\,T.\n$$\nSubstituting into the BED gives\n$$\n\\mathrm{BED} = D + \\frac{1}{\\alpha/\\beta}\\,D^{2}\\,G = D\\left[1 + \\frac{G\\,D}{\\alpha/\\beta}\\right].\n$$\n\nThe Equivalent Dose in $2\\,\\text{Gy}$ fractions (EQD2) is defined as the total dose in $2\\,\\text{Gy}$ fractionation that produces the same BED:\n$$\n\\mathrm{BED} = \\mathrm{EQD2}\\left(1 + \\frac{2}{\\alpha/\\beta}\\right) \\quad \\Longrightarrow \\quad \\mathrm{EQD2} = \\frac{\\mathrm{BED}}{1 + \\frac{2}{\\alpha/\\beta}}.\n$$\n\nAssumptions used:\n- The dose rate is treated as approximately constant over the implant, i.e., $R(t) \\approx \\dot{D}$, and delivery is continuous without gaps.\n- Sublethal damage repair follows mono-exponential kinetics with rate constant $\\mu$ that is constant over the irradiation.\n- Repopulation and other time-dependent biological processes (e.g., redistribution, reoxygenation) are neglected over the short implant duration.\n- The total dose $D$ is taken as the prescribed $85\\,\\text{Gy}$ delivered over $T = 120\\,\\text{h}$. The stated $\\dot{D} = 0.7\\,\\text{Gy}\\,\\text{h}^{-1}$ implies $\\dot{D} \\times T \\approx 84\\,\\text{Gy}$; we proceed with $D = 85\\,\\text{Gy}$ and $T = 120\\,\\text{h}$ as given. Note that $G$ depends only on $T$ and $\\mu$ for constant rate delivery.\n\nNumerical evaluation:\n- Given $T = 120\\,\\text{h}$ and $\\mu = 0.3\\,\\text{h}^{-1}$, we have $\\mu T = 36$. Then\n$$\nG = \\frac{2}{36}\\left(1 - \\frac{1 - \\exp(-36)}{36}\\right).\n$$\nSince $\\exp(-36) \\approx 2.319 \\times 10^{-16}$ is negligible,\n$$\nG \\approx \\frac{2}{36}\\left(1 - \\frac{1}{36}\\right) = \\frac{1}{18}\\cdot\\frac{35}{36} = \\frac{35}{648} \\approx 0.054012345679.\n$$\n- With $D = 85\\,\\text{Gy}$ and $\\alpha/\\beta = 3\\,\\text{Gy}$,\n$$\n\\mathrm{BED} = 85\\left[1 + \\frac{(0.054012345679)\\times 85}{3}\\right] = 85\\left[1 + \\frac{4.591049382715}{3}\\right] = 85 \\times 2.530349794238 \\approx 215.079732510\\,\\text{Gy}.\n$$\n- Finally,\n$$\n\\mathrm{EQD2} = \\frac{\\mathrm{BED}}{1 + \\frac{2}{3}} = \\frac{215.079732510\\,\\text{Gy}}{\\frac{5}{3}} = 215.079732510\\,\\text{Gy} \\times \\frac{3}{5} \\approx 129.047839506\\,\\text{Gy}.\n$$\n\nRounded to three significant figures and expressed in Gray, the EQD2 is $129\\,\\text{Gy}$.",
            "answer": "$$\\boxed{129}$$"
        }
    ]
}